Usana Health Sciences
USNA on NYSE. USANA Health Sciences sells nutritional supplements and skincare products to customers worldwide. Market value $274m.
Price checks use the past 12 months to June 2026. Quality checks use five annual reports, the latest for the year to December 2025.
We can't read total debt from the filing, so debt is left out.
Recent profit includes a big one-time charge, so we price the company excluding that charge.
Should I look at this?
Not a fit for our list right now
Why it could be worth it
See Health care stocks that passed both tests
This is not advice. Check the numbers below.
For every $100 of what the whole company costs, it produced $5.82 of spare cash in the past 12 months. A savings account pays about $4.
The filings do not give us enough to work this out.
The filings do not give us enough to work this out.
Quality score: 53 of 100. Price score: 58 of 100. Our list needs 70 on quality and 60 on price.
$14.83 a share, 18% above its 1-year low
Over the past year the price has ranged from $12.57 to $26.76.
Pays no dividend
Prices from Tuesday’s close (6 October).
Five years of cash, in billions
Spare cash swings from quarter to quarter here: $16 million in the past 12 months, $9 million in the year to December 2025.
| Revenue | |||||
| Revenue | $1.2bn | $999m | $921m | $855m | $925m |
| Operating margin | |||||
| Operating margin | 14.3% | 10.8% | 10.1% | 7.8% | 4.0% |
| Debt to equity | |||||
| Debt to equity | n/a | n/a | n/a | n/a | n/a |
| Shares outstanding | |||||
| Shares outstanding | 0.02bn | 0.02bn | 0.02bn | 0.02bn | 0.02bn |
Health checks
- Free cash flow positive5 of 5 years
- Accounting looks honest (Beneish)Not enough data
- Financial strength (Piotroski)7 of 8 checks we could run
- Profit backed by cash (accruals)Yes
- DebtUnknown
- Revenue growth, five yearsShrinking, 4.0% a year
- Buying back its own sharesYes, 4% fewer since 2021
The quarter to June 2026
How the business did, compared with the same quarter a year earlier.
- Sales: $223 million last quarter, down 5% on a year ago.
- A loss of $21 million, after a profit of $10 million a year ago.
- It keeps 0 cents of each $1 of sales as operating profit, down from 6 cents a year earlier.
- Spare cash over the past 12 months: $16 million, down from $51 million.
- About the same number of shares as a year ago.
- Sales grew on a year ago in 3 of the last 4 quarters.
| Quarter to | Amount |
|---|---|
| September 2024 | $200m |
| December 2024 | $214m |
| March 2025 | $250m |
| June 2025 | $236m |
| September 2025 | $214m |
| December 2025 | $226m |
| March 2026 | $250m |
| June 2026 | $223m |
| Quarter to | Amount |
|---|---|
| September 2024 | $11m |
| December 2024 | $4m |
| March 2025 | $9m |
| June 2025 | $10m |
| September 2025 | -$7m |
| December 2025 | -$2m |
| March 2026 | $8m |
| June 2026 | -$21m |
From the company's quarterly reports to the SEC.
Dates
- Next results (estimated)
- n/a
- Last annual report (10-K)
- 16 March 2026
- Next quarterly (estimated, 10-Q)
- 12 November 2026
Who owns it
4 long-term investors we follow own it, unchanged from 4 last quarter. 138 funds in all.
- LSV Asset ManagementJosef Lakonishok
- Value
- $162,000
- Share of fund
- <0.1%
- Barrow HanleyBarrow Hanley team
- Value
- $4,526
- Share of fund
- <0.1%
| Fund | Value | Share of that fund | Change |
|---|---|---|---|
| Pzena Investment ManagementRichard Pzena | $26m | <0.1% | Added |
| Royce & AssociatesChuck Royce | $884,039 | <0.1% | Cut |
| LSV Asset ManagementJosef Lakonishok | $162,000 | <0.1% | |
| Barrow HanleyBarrow Hanley team | $4,526 | <0.1% |
Largest holders overall
- Nantahala Capital Management$35mAdded
- BlackRock$33mAdded
- Pzena Investment Management$26mAdded
- Renaissance Technologies$20mCut
- Dimensional Fund Advisors LP$18m
- Vanguard Capital Management$10m
- Creative Planning$9mAdded
- AQR Capital Management$9mAdded
- Vanguard Portfolio Management$8mAdded
- Geode Capital Management$6mAdded
From 13F filings for the quarter ended 30 June 2026.
Big holders and activists
3 investors own more than 5%.
- Gull Global LimitedInsider or founderat least 40.1%(filed with 1 related holder)Since 26 March 2026
What they said
On May 13, 2008, Dr. Wentz, Gull Holdings, Ltd., an Isle of Man company indirectly owned and controlled by Dr. Wentz ("Gull Holdings"), together with certain other persons (Dr. Wentz, Gull Holdings and such other persons, collectively, the "Original Reporting Persons") announced…
Read the filing - Pzena Investment ManagementPassive investor6.6%Since 30 September 2025
- Renaissance Technologies LLCPassive investorat least 5.2%(filed with 1 related holder)Since 30 June 2026
- Dimensional Fund Advisors LPPassive investorSold down below 5%Since 31 December 2025
- BlackRock, Inc.Passive investorSold down below 5%Since 31 December 2025
- The Vanguard GroupPassive investorSold down below 5%Since 13 March 2026
| Holder | Stake | Since | |
|---|---|---|---|
Gull Global Limited Insider or founder | at least 40.1% (filed with 1 related holder) | 26 March 2026 | What they saidOn May 13, 2008, Dr. Wentz, Gull Holdings, Ltd., an Isle of Man company indirectly owned and controlled by Dr. Wentz ("Gull Holdings"), together with certain other persons (Dr. Wentz, Gull Holdings and such other persons, collectively, the "Original Reporting Persons") announced… Read the filing |
Pzena Investment Management Passive investor | 6.6% | 30 September 2025 | |
Renaissance Technologies LLC Passive investor | at least 5.2% (filed with 1 related holder) | 30 June 2026 | |
Dimensional Fund Advisors LP Passive investor | Sold down below 5% | 31 December 2025 | |
BlackRock, Inc. Passive investor | Sold down below 5% | 31 December 2025 | |
The Vanguard Group Passive investor | Sold down below 5% | 13 March 2026 |
From Schedule 13D and 13G filings: anyone owning more than 5% must file one.
What insiders did
No insider bought shares on the open market in the last 12 months. 9 sold $990,588.
- Neidig BrentCHIEF COMMERCIAL OFFICERSold
- Date
- 16 June 2026
- Shares
- 5,002
- Price
- $19.45
- Value
- $97,289
- Neidig BrentCHIEF COMMERCIAL OFFICERSold
- Date
- 15 June 2026
- Shares
- 909
- Price
- $20.01
- Value
- $18,189
- Neidig BrentCHIEF COMMERCIAL OFFICERSold
- Date
- 12 June 2026
- Shares
- 1,602
- Price
- $20.15
- Value
- $32,280
- Jones Paul A.CHIEF PEOPLE OFFICERSold
- Date
- 8 June 2026
- Shares
- 5,561
- Price
- $18.50
- Value
- $102,879
- Fleming John TurmanDirectorSold
- Date
- 1 June 2026
- Shares
- 2,450
- Price
- $17.93
- Value
- $43,929
- Jones Paul A.CHIEF PEOPLE OFFICERSold
- Date
- 28 May 2026
- Shares
- 6,813
- Price
- $18.95
- Value
- $129,106
- IIEKKING G DOUGCHIEF FINANCIAL OFFICERSold
- Date
- 27 May 2026
- Shares
- 5,360
- Price
- $18.75
- Value
- $100,500
- FULLER GILBERT ADirectorSold
- Date
- 22 May 2026
- Shares
- 1,057
- Price
- $18.66
- Value
- $19,724
- Foukas JoshuaCHIEF LEGAL OFFICERSold
- Date
- 7 May 2026
- Shares
- 3,791
- Price
- $19.82
- Value
- $75,138
- FULLER GILBERT ADirectorSold
- Date
- 20 March 2026
- Shares
- 1,058
- Price
- $17.00
- Value
- $17,986
| Date | Who | Did | Shares | Price | Value |
|---|---|---|---|---|---|
| 16 June 2026 | Neidig Brent CHIEF COMMERCIAL OFFICER | Sold | 5,002 | $19.45 | $97,289 |
| 15 June 2026 | Neidig Brent CHIEF COMMERCIAL OFFICER | Sold | 909 | $20.01 | $18,189 |
| 12 June 2026 | Neidig Brent CHIEF COMMERCIAL OFFICER | Sold | 1,602 | $20.15 | $32,280 |
| 8 June 2026 | Jones Paul A. CHIEF PEOPLE OFFICER | Sold | 5,561 | $18.50 | $102,879 |
| 1 June 2026 | Fleming John Turman Director | Sold | 2,450 | $17.93 | $43,929 |
| 28 May 2026 | Jones Paul A. CHIEF PEOPLE OFFICER | Sold | 6,813 | $18.95 | $129,106 |
| 27 May 2026 | IIEKKING G DOUG CHIEF FINANCIAL OFFICER | Sold | 5,360 | $18.75 | $100,500 |
| 22 May 2026 | FULLER GILBERT A Director | Sold | 1,057 | $18.66 | $19,724 |
| 7 May 2026 | Foukas Joshua CHIEF LEGAL OFFICER | Sold | 3,791 | $19.82 | $75,138 |
| 20 March 2026 | FULLER GILBERT A Director | Sold | 1,058 | $17.00 | $17,986 |
From Form 4 filings: insiders must report trades in their own company's shares within two days.
What could go wrong
- Sales have shrunk: 4.0% a year.
Whether the price already reflects the risks is what the deep dive is for.
The deep dive
Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.
- What the business is worth, as a range, and the margin of safety at today’s price
- Prices to start buying, buy, and buy hard
- The three things that would make this a mistake
- Every number footnoted to the filing it came from
Your first deep dive is free.
Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.